Jeffrey M. Leiden

2012 - Vertex Pharmaceuticals

In 2012, Jeffrey M. Leiden earned a total compensation of $5.7M as Chairman, President & CEO at Vertex Pharmaceuticals, a 47% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,088,000
Option Awards$2,556,234
Salary$1,000,000
Other$12,450
Total$5,656,684

Leiden received $2.6M in option awards, accounting for 45% of the total pay in 2012.

Leiden also received $2.1M in non-equity incentive plan, $1M in salary and $12.5K in other compensation.

Rankings

In 2012, Jeffrey M. Leiden's compensation ranked 1,033rd out of 11,487 executives tracked by ExecPay. In other words, Leiden earned more than 91.0% of executives.

ClassificationRankingPercentile
All
1,033
out of 11,487
91st
Division
Manufacturing
377
out of 4,252
91st
Major group
Chemicals And Allied Products
88
out of 1,200
93rd
Industry group
Drugs
49
out of 922
95th
Industry
Pharmaceutical Preparations
44
out of 697
94th
Source: SEC filing on April 30, 2015.

Leiden's colleagues

We found six more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2012.

2012

Matthew Emmens

Vertex Pharmaceuticals

Chief Executive Officer

2012

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2012

Peter Mueller

Vertex Pharmaceuticals

Chief Scientific Officer

2012

David Howton

Vertex Pharmaceuticals

Chief Legal Officer

2012

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2012

Kenneth Horton

Vertex Pharmaceuticals

Chief Legal Officer

News

You may also like